Tabuk Cement Company (3090.SR)
SAR 12.48
(0.48%)
SAR 12.48
(0.48%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 72.63 Million | 105.23 Million | 59.82 Million | 113.75 Million | 111.14 Million | 19.71 Million |
| Net Income | 19.74 Million | 20.96 Million | 22.8 Million | 59.64 Million | 24.18 Million | -98.94 Million |
| Depreciation & Amortization | 60.48 Million | 60.85 Million | 60.61 Million | 72.35 Million | 89.89 Million | 105.99 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -18.92 Million | 11.19 Million | -18.39 Million | 978.69 Thousand | -9.72 Million | -42.29 Million |
| Other non-cash items | 11.33 Million | 12.22 Million | -5.18 Million | -19.22 Million | 6.78 Million | 118.66 Million |
| Investing Cash Flow | -17.77 Million | -10.57 Million | 3.85 Million | 52.31 Thousand | -12.92 Million | 3.86 Million |
| Investments in PPE | -17.77 Million | -10.57 Million | -11.34 Million | -10.04 Million | -13.59 Million | -1.75 Million |
| Acquisitions | - | - | - | - | 674.42 Thousand | 5.61 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 15.2 Million | 10.09 Million | - | - |
| Other Investing Activities | -1.56 Million | -343.14 Thousand | 14.92 Million | 8.7 Million | -1.6 Million | 3.86 Million |
| Financing Cash Flow | -64.91 Million | -95.79 Million | -56.29 Million | -87.21 Million | -106.12 Million | -30.64 Million |
| Debt repayment | -63.47 Million | -63.47 Million | -47.6 Million | -71.4 Million | -82.13 Million | -7.51 Million |
| Dividends payments | -680.42 Thousand | -23.2 Million | -614.51 Thousand | -2.94 Million | -173.63 Thousand | -483.95 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -4.96 Million | -9.11 Million | -8.07 Million | -12.87 Million | -23.8 Million | -30.64 Million |
| Accounts receivables | -8.92 Million | -10.94 Million | -4.54 Million | -1.87 Million | -2.19 Million | 6.65 Million |
| Accounts payables | 4.64 Million | -4.15 Million | 16.94 Million | -11.74 Million | 6.69 Million | -1.87 Million |
| Inventory | -16.05 Million | 34.13 Million | -8.49 Million | 14.59 Million | -6.92 Million | -46.08 Million |
| Other working capital | 1.4 Million | -7.84 Million | -22.3 Million | -4.46 Million | -7.31 Million | -995 Thousand |
| Cash at beginning of period | 46.95 Million | 48.08 Million | 40.69 Million | 14.1 Million | 22 Million | 29.06 Million |
| Cash at end of period | 36.89 Million | 46.95 Million | 48.08 Million | 40.69 Million | 14.1 Million | 22 Million |
| Capital Expenditure | -17.77 Million | -10.57 Million | -11.34 Million | -10.04 Million | -13.59 Million | -1.75 Million |
| Effect of forex changes on cash | -1.00 | - | - | - | - | - |
| Net cash flow / Change in cash | -10.05 Million | -1.12 Million | 7.38 Million | 26.58 Million | -7.9 Million | -7.06 Million |
| Free Cash Flow | 54.85 Million | 94.66 Million | 48.48 Million | 103.71 Million | 97.54 Million | 17.96 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 31.33 Million | 16.11 Million | 19.74 Million | -5.42 Million | -3.19 Million | 10.91 Million |
| Depreciation & Amortization | 9.63 Million | 15.95 Million | 60.48 Million | 15.91 Million | 15.09 Million | 13.11 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 2.37 Million | -15.32 Million | -18.92 Million | 1.19 Million | 7.73 Million | -3.56 Million |
| Other non-cash items | 21.71 Million | 50.38 Million | 11.33 Million | 3.91 Million | 2.85 Million | 2.3 Million |
| Investing Cash Flow | -2.31 Million | -6.51 Million | -17.77 Million | -3.03 Million | -7.14 Million | -4.35 Million |
| Investments in PPE | -2.31 Million | -6.51 Million | -17.77 Million | -3.03 Million | -6.82 Million | -4.67 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 6.78 Million | - | - | - | -321.08 Thousand | 321.08 Thousand |
| Financing Cash Flow | -16.51 Million | -16.39 Million | -64.91 Million | -16.48 Million | -17.35 Million | -17.83 Million |
| Debt repayment | -15.86 Million | -15.86 Million | -63.47 Million | -15.86 Million | -15.86 Million | -15.85 Million |
| Dividends payments | -117.43 Thousand | - | -680.42 Thousand | -268.78 Thousand | -57.11 Thousand | -16.79 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -526.11 Thousand | - | - | - | -1.43 Million | -1.95 Million |
| Accounts receivables | -14.6 Million | -27.46 Million | -8.92 Million | -1.99 Million | 14.95 Million | 14.84 Million |
| Accounts payables | -1.94 Million | 2.36 Million | 4.64 Million | -4.85 Million | -14.95 Million | -14.84 Million |
| Inventory | 9.5 Million | 10.44 Million | -16.05 Million | 6.05 Million | -15 Million | -13.57 Million |
| Other working capital | -206.16 Thousand | -684.92 Thousand | 1.4 Million | 1.98 Million | 22.74 Million | 10 Million |
| Cash at beginning of period | 34.55 Million | 36.89 Million | 46.95 Million | 40.8 Million | 42.82 Million | 42.24 Million |
| Cash at end of period | 54.48 Million | 34.55 Million | 36.89 Million | 36.89 Million | 40.8 Million | 42.82 Million |
| Capital Expenditure | -2.31 Million | -6.51 Million | -17.77 Million | -3.03 Million | -6.82 Million | -4.67 Million |
| Effect of forex changes on cash | - | - | -1.00 | - | - | - |
| Net cash flow / Change in cash | 19.92 Million | -2.33 Million | -10.05 Million | -3.91 Million | -2.01 Million | 580.16 Thousand |
| Free Cash Flow | 36.43 Million | 14.05 Million | 54.85 Million | 12.57 Million | 15.66 Million | 18.09 Million |
8377
POND
1721
TRIP
DRUG
HAIN